The ADK Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the adenosine kinase (ADK) gene has been disrupted by CRISPR/Cas9-mediated gene targeting. This polyclonal pool provides a heterogeneous loss-of-function model for investigating adenosine metabolism and signaling without clonal selection.
The parental Jurkat E6-1 cell line is an immortalized human CD4+ T lymphoblast line, originally derived from peripheral blood of a 14-year-old male with acute T cell leukemia. Jurkat cells serve as a widely utilized model for T cell receptor signaling, leukemia biology, and immunological studies due to their robust growth and well-characterized signaling pathways.
ADK is the primary enzyme responsible for phosphorylating adenosine to AMP, thereby controlling intracellular adenosine concentrations and indirectly regulating extracellular adenosine availability. Key upstream regulators include adenosine, ATP, cAMP, TNF-??, and hypoxia. Downstream, ADK-generated AMP feeds into purine salvage and the methionine cycle, impacting S-adenosylmethionine levels and subsequent DNA methylation. ADK disruption leads to elevated intracellular adenosine, which is exported via equilibrative nucleoside transporters (ENT1) and activates adenosine receptors (A1, A2A, A2B, A3). This triggers G-protein-coupled signaling cascades involving cAMP and AMPK, altering immune cell function. Additionally, adenosine accumulation inhibits S-adenosylhomocysteine hydrolase (SAHH) and reduces S-adenosylmethionine production by MAT2A, thereby diminishing methyltransferase activity and affecting DNA and protein methylation. Thus, ADK sits at the nexus of adenosine metabolism, receptor signaling, and epigenetic regulation.
In Jurkat T cells, ADK knockout recapitulates key features of adenosine-driven immunosuppression observed in tumor microenvironments and inflammatory conditions. The consequent rise in extracellular adenosine potently modulates T cell activation via A2A adenosine receptor engagement, leading to elevated intracellular cAMP and impaired effector functions. This model enables dissection of adenosine-mediated checkpoints in T cell signaling, survival, and cytokine production, and provides a platform for studying adenosine receptor pharmacology and resistance mechanisms in leukemia.
Typical research applications include elucidating adenosine signaling in T cell activation, modeling tumor microenvironment immunosuppression, and testing small-molecule adenosine kinase inhibitors. Experimental assays applicable to this model include Western blotting for ADK and downstream signaling proteins, LC-MS/MS quantification of adenosine and AMP, flow cytometric analysis of adenosine receptor expression and T cell activation markers (CD69, IL-2), cAMP ELISA, and DNA methylation profiling. These polyclonal knockout cells are a versatile tool for both mechanistic studies and drug discovery programs. For further inquiries or custom requests, please contact Ascent Research.
